Abstracts Archive - Page 1826 of 2425 - ACR Meeting Abstracts

Abstract Number: 2055 • 2015 ACR/ARHP Annual Meeting
A Phase III, Randomized, Double-Blind Clinical Study Comparing SB4, an Etanercept Biosimilar, with Etanercept Reference Product (Enbrel®) in Patients with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy (52-week Results)
Jiri Vencovsky¹, Anna Sylwestrzak², Piotr Leszczyñski³, Wieslawa Porawska⁴, Asta Baranauskaite⁵, Vira Tseluyko⁶, Vyacheslav Zhdan⁷, Barbara Stasiuk⁸, Roma Milasiene⁹, Aaron Alejandro Barrera Rodriguez¹⁰, Soo Yeon Cheong¹¹, Jeehoon Ghil¹¹ and Paul Emery¹², ¹Rheumatology, Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ²NZOZ Medica Pro Familia Sp. z o.o., Warsaw, Poland, ³Rheumatology and Rehabilitation, Poznan University of Medical Sciences, Poznan, Poland, ⁴Poznanski Osrodek Medyczny NOVAMED, Poznan, Poland, ⁵Lithuanian University of Health Sciences, Kaunas, Lithuania, ⁶Internal Medicine and Rheumatology, Kharkiv Medical Academy of Postgraduate Education, Kharkiv, Ukraine, ⁷M.V.Sklifosovskyi Poltava Regional Clinical Hospital, Poltava, Ukraine, ⁸Medicome Sp. z o.o., Oswiecim, Poland, ⁹Klaipeda University Hospital, Klaipeda, Lithuania, ¹⁰Unidad de Atención Medica e Investigación en Salud (UNAMIS), Yucatán, Mexico, ¹¹Samsung Bioepis Co., Ltd., Incheon, South Korea, ¹²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: SB4 is a biologic agent developed as a biosimilar of the etanercept reference product (ETN). This study was a randomized, double-blind, multicenter study and…
Abstract Number: 2056 • 2015 ACR/ARHP Annual Meeting
A Randomized, Double-Blind, Phase III Study Comparing SB2, an Infliximab Biosimilar, to the Infliximab Reference Product (Remicade®) in Patients with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy: 54-Week Results
Jung-Yoon Choe¹, Nenad Prodanovic², Jaroslaw Niebrzydowski³, Ivan Staykov⁴, Eva Dokoupilova⁵, Asta Baranauskaite⁶, Roman Yatsyshyn⁷, Mevludin Mekic⁸, Wieslawa Porawska⁹, Hana Ciferska¹⁰, Krystyna Jedrychowicz-Rosiak¹¹, Agnieszka Zielinska¹², Jasmine Choi¹³, Young Hee Rho¹³ and Josef S. Smolen¹⁴, ¹Division of Rheumatology, Daegu Catholic University Medical Center, Daegu, South Korea, ²Clinical Center Banja Luka, Banja Luka, Bosnia, ³Medica Pro Familia, Gdynia, Poland, ⁴MHAT "Dr. Ivan Seliminski", AD, Sliven, Bulgaria, ⁵MEDICAL PLUS s.r.o, Uherske Hradiste, Czech Republic, ⁶Lithuanian University of Health Sciences, Kaunas, Lithuania, ⁷SHEI Ivano-Frankivsk NMU, Ivano-Frankivsk, Ukraine, ⁸University Clinic Centre Sarajevo, Sarajevo, Bosnia, ⁹Poznanski Osrodek Medyczny NOVAMED, Poznan, Poland, ¹⁰Revmatologicky ustav, Praha 2, Czech Republic, ¹¹MCBK S.C., Grodzisk Mazowiecki, Poland, ¹²Medica Pro Familia Sp. z o.o. Spolka Komandytowo-Akcyjna, Warszawa, Poland, ¹³Samsung Bioepis Co., Ltd., Incheon, South Korea, ¹⁴Medical University of Vienna, Vienna, Austria
Background/Purpose: SB2 is developed as a biosimilar of the infliximab reference product (INF). 30-week efficacy and safety results from a randomized phase III study were…
Abstract Number: 2057 • 2015 ACR/ARHP Annual Meeting
Antibodies to Infliximab in Remicade-Treated Rheumatic Patients Show Identical Reactivity Towards Biosimilars
Begoña Ruiz-Argüello¹, Ainara Maguregui¹, Ainhoa Ruiz del Agua¹, Dora Pascual-Salcedo², Ana Martínez², Teresa Jurado³, Chamaida Plasencia⁴, Alejandro Balsa⁵, Francisca Llinares-Tello⁶, José Rosas⁷, Nerea Torres¹, Antonio Martínez¹ and Daniel Nagore¹, ¹R&D, Progenika-Grifols, Derio, Spain, ²Immunology Unit, La Paz University Hospital-Immunology, Madrid, Spain, ³Immunology, La Paz University Hospital-Idipaz, Madrid, Spain, ⁴Rheumatology Unit, La Paz University Hospital-Rheumatology, Madrid, Spain, ⁵Rheumatology, La Paz University Hospital-Rheumatology Department, Madrid, Spain, ⁶Clinical Analysis, Hospital Marina Baixa, Clinical Analysis, Villajoyosa, Spain, ⁷Rheumatology, Hospital Marina Baixa, Villajoyosa, Spain
Background/Purpose: Infliximab (IFX) is the most immunogenic of anti-TNFα drugs available to treat patients with rheumatic diseases. The recent approval of the first infliximab biosimilars in…
Abstract Number: 2058 • 2015 ACR/ARHP Annual Meeting
Efficacy and Safety of Rituximab Biosimilar Candidate (CT-P10) and Innovator Rituximab in Patients with Rheumatoid Arthritis: Results from Phase I Randomized Controlled Trial over 72 Weeks
Dae-Hyun Yoo¹, Won Park², Chang-Hee Suh³, Seung-Cheol Shim⁴, Slawomir Jeka⁵, Fidencio Cons Molina⁶, Pawel Hrycaj⁷, Wolfgang Spieler⁸, Piotr Wiland⁹, Jan Brzezicki¹⁰, Eun Young Lee¹¹, Francisco G. Medina-Rodriguez¹², Pavel Shesternya¹³, Sebastiao Radominski¹⁴, Marina Stanislav¹⁵, Volodymyr Kovalenko¹⁶, Donghyuk Sheen¹⁷, Leysan Myasoutova¹⁸, Mie Jin Lim¹⁹, Jung-Yoon Choe²⁰, Taek S. Kwon²¹ and Sang Joon Lee²¹, ¹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Inha University Hospital, Incheon, South Korea, ³Department of Rheumatology, Ajou University Hospital, Suwon, South Korea, ⁴Department of Internal Medicine, Chungnam National University Hospital, Daejeon, South Korea, ⁵University Hospital Nr 2 Dr. Jan Biziel, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Clinic of Rheumatology and Connective Tissue Diseases, Bydgoszcz, Poland, ⁶Centro de Investigacion en Artritis y Osteoporosis, Mexicali, Mexico, ⁷Department of Rheumatology and Clinical Immunology, Poznan University of Medical Sciences, Poznan, Poland, ⁸Osteologie und Rheumatologie, ZeFOR GmbH Zentrum für Forschung, Zerbst, Germany, ⁹Department of Rheumatology, Medical University of Wroclaw, Wroclaw, Poland, ¹⁰Wojewodzki Szpital Zespolony w Elablagu, Elblag, Poland, ¹¹Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea, ¹²Rheumatology, LaSalle University, Mexico City, Mexico, ¹³Rheumatology Department, Krasnoyarsk State Medical University, Krasnoyarsk, Russia, ¹⁴CETI-Centro de estudos em Terapias Inovadoras, Universidade Federal do Parana, Curitiba, Brazil, ¹⁵Research Rheumatology Institute n. a. V.A. Nassonova, Moscow, Russia, ¹⁶Section of Non-coronarogenic Myocardial Diseases and Clinical Rheumatology, National Scientific Center, Kiev, Ukraine, ¹⁷Rheumatology, Eulji University Hospital, Daejeon, South Korea, ¹⁸City Reumatology Center, Research Medical Complex Vashe Zdorovie, Kazan, Russia, ¹⁹Division of Rheumatology, Departments of Internal Medicine, Inha University Hospital, Incheion, South Korea, ²⁰Internal Medicine, Catholic University of Daegu, School of Medicine, Daegu, South Korea, ²¹CELLTRION, Inc., Incheon, South Korea
Background/Purpose: CT-P10 is a biosimilar candidate of innovator rituximab (RTX). PK profile and clinical data up to week 24 has been reported at ACR 20131.…
Abstract Number: 2059 • 2015 ACR/ARHP Annual Meeting
Tumor Necrosis Factor Inhibitor Tapering Induced Radiographic Progression Is Driven By Weighted Mean Disease Activity over Time, Not Flaring or Lower TNFi Exposition
Alfons A. den Broeder¹, Chantal A.M. Bouman¹, Aatke van der Maas², Frank H.J. van den Hoogen¹, Noortje van Herwaarden¹ and R. Landewe³, ¹Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ²Hengstdal 3, Sint Maartenskliniek, Nijmegen, Netherlands, ³Department of Internal Medicine, Division of Rheumatology, University Hospital Maastricht, Maastricht, Netherlands
Background/Purpose: DRESS, a randomized controlled strategy trial (RCT)1investigating disease activity guided tapering of etanercept and adalimumab compared to usual care in RA patients, indicated that…
Abstract Number: 2060 • 2015 ACR/ARHP Annual Meeting
Microscopic Bowel Inflammation in Spondyloarthritis As a Baseline Predictor of Anti-TNF Response
Heleen Cypers, Gaëlle Varkas, Filip van Den Bosch and Dirk Elewaut, Rheumatology, Ghent University Hospital, VIB, Ghent, Belgium
· Background/Purpose: Microscopic bowel inflammation without associated gastro-intestinal symptoms is present in up to 50% of spondyloarthritis (SpA) patients. Two types of inflammation are distinguished based…
Abstract Number: 2061 • 2015 ACR/ARHP Annual Meeting
Uncovering Crohn’s Disease in Patients with Spondyloarthropathies Using Videocapsule Endoscopy
Uri Kopylov¹, Craig Watts², Michael Starr^3,4, Serge Dionne⁵, Jamie Koenekoop⁵ and Ernest Seidman⁵, ¹Gastroenterolog, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ²Department of Rheumatology, McGill University and Montreal General Hospital, Sainte-Anne-de-Bellevue, QC, Canada, ³Rheumatology, McGill University, Montreal, QC, Canada, ⁴Rheumatology, McGill University Health Centre, Montreal, QC, Canada, ⁵Gastroenterology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Inflammatory bowel disease (IBD) is clinically associated with spondylarthropathies (SpA) in 5-15% of cases. Protocol colonoscopic assessment demonstrated asymptomatic inflammation characteristic of Crohn’s disease…
Abstract Number: 2062 • 2015 ACR/ARHP Annual Meeting
How Reliable Is Self-Evaluation of Symptoms of Inflammatory Back Pain By Patients?
Denis Poddubnyy¹, Inge Spiller¹, Joachim Sieper¹ and Martin Rudwaleit^1,2, ¹Charité Universitätsmedizin Berlin, Berlin, Germany, ²Klinikum Bielefeld, Bielefeld, Germany
Background/Purpose: Inflammatory back pain (IBP) is regarded as an important clinical parameter of axial spondyloarthritis (axSpA) and is often used in a diagnostic approach. Usually…
Abstract Number: 2063 • 2015 ACR/ARHP Annual Meeting
The Survival Impact of Statins in Psoriasis and Psoriatic Arthritis: A General Population-Based Cohort Study
Sian Yik Lim¹, Na Lu² and Hyon K. Choi², ¹Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Given their lipid-lowering and anti-inflammatory properties, statins may have dual cardioprotective and anti-rheumatic benefits in psoriasis or psoriatic arthritis. These effects may confer survival…
Abstract Number: 2064 • 2015 ACR/ARHP Annual Meeting
Increase in IL-31 Serum Level in Recent Onset Spondyloarthritis – Data from the DESIR Cohort
Nicolas Rosine Jr.¹, Adrien Etcheto², Anna Moltó³, Yassine Taoufik⁴, Houria Chavez⁴, Christian Roux⁵, Karine Briot⁵, Maxime Dougados⁶ and Corinne Miceli⁵, ¹Rheumatology Department, Hôpital Kremlin Bicêtre, Paris, France, ²Rheumatology B, Rheumatology B Department, Paris-Descartes University, Cochin Hospital, Paris, France, ³Paris Descartes University, Rheumatology Department, Cochin Hospital, AP-HP. INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité,, Paris, France, ⁴Biologic Immunology, Hopital Bicetre, Université Paris Sud, AP-HP, Kremlin Bicetre, France, ⁵Rheumatology B Department, Hôpital Cochin, Paris, France, ⁶Rheumatology B Department,, Paris-Descartes University, APHP, Cochin Hospital, Paris, France
Background/Purpose: IL-31 is a newly-described cytokine mainly produced by activated Th2 cells. IL-31 acts through IL31-RA and oncostatin heterodimeric receptors that activate STAT3 and STAT5. So far, IL31 has…
Abstract Number: 2065 • 2015 ACR/ARHP Annual Meeting
Verification of Novel Soluble Biomarkers That Differentiate Patients with Psoriatic Arthritis from Those with Psoriasis without Psoriatic Arthritis
Vinod Chandran¹, Daniela Cretu^2,3, Lisa Gao⁴, Kun Liang⁴, Antoninus Soosaipillai³ and Eleftherios Diamandis^2,3,5, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada, ³Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada, ⁴Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, ⁵Department of Clinical Biochemistry, University Health Network, Toronto, ON, Canada
Background/Purpose: There is a high prevalence of undiagnosed psoriatic arthritis (PsA) in psoriasis patients. Therefore identifying soluble biomarkers for PsA will help in screening psoriasis…
Abstract Number: 2066 • 2015 ACR/ARHP Annual Meeting
Elevated Innate, Adaptive, and TNF-Superfamily Soluble Inflammatory Mediators Mark Impending Disease Flare, While Regulatory Mediators Distinguish Lack of Impending Disease Flare in African-American SLE Patients with Active Disease
Melissa E. Munroe¹, Evan G. Vista², Joan T. Merrill³, Joel M. Guthridge¹, Virginia C. Roberts¹ and Judith A. James⁴, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Rheumatology and Clinical Immunology, University of Santo Tomas, Taguig City, Philippines, ³Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Arthritis and Clinical Immunology, University of Oklahoma Health Sciences Center and Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: SLE is a multifaceted disease characterized by immune dysregulation and varied disease activity. Identifying mechanistic mediators of altered disease activity would help prevent damage…
Abstract Number: 2067 • 2015 ACR/ARHP Annual Meeting
De-Convolution of Whole Blood Transcriptomic Data from a Phase IIb, Randomized, Double-Blind, Placebo-Controlled Trial of Abatacept in Systemic Lupus Erythematosus
S Bandyopadhyay¹, SE Connolly¹, O Jabado¹, S Kelly¹, M Maldonado¹, R Westhovens², P Nash³, JT Merrill⁴ and R Townsend¹, ¹Bristol-Myers Squibb, Princeton, NJ, ²University Hospitals KU Leuven, Leuven, Belgium, ³University of Queensland, Brisbane, Australia, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: The Phase IIb IM101-042 trial was a randomized, double-blind, placebo-controlled trial of abatacept (ABA) in systemic lupus erythematosus patients (pts) with polyarthritis, discoid lesions…
Abstract Number: 2068 • 2015 ACR/ARHP Annual Meeting
Low Complement Is Associated with SLE Classification Criteria and Organ Damage
Laura Durcan¹, Wei Fu² and Michelle Petri¹, ¹Rheumatology, Johns Hopkins University Hospital, Baltimore, MD, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Low complements are included in the SLICC classification criteria for systemic lupus erythematosus (SLE) but are not considered in the ACR classification. As a…
Abstract Number: 2069 • 2015 ACR/ARHP Annual Meeting
High Interferon Gene Signature Is Associated with Increased Disease Activity, Reduced Complement C3 and C4, and Increased Oral Corticosteroid Use in Systemic Lupus Erythematosus (SLE)
K Ranade, L Wang, P Brohawn, W Greth, J Drappa and G Illei, MedImmune, Gaithersburg, MD
Background/Purpose: Increased expression of genes inducible by type 1 interferons has been observed in a subset of patients with systemic lupus erythematosus (SLE). Oral corticosteroids…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].